Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus

11th Mar, 2026

Rheumatology

The New England Journal of Medicine

In patients with SLE without advanced lupus nephritis, obinutuzumab plus standard therapy was superior to placebo plus standard therapy in conferring and sustaining a clinically meaningful reduction in disease activity over 52 weeks.

Published By: The New England Journal of Medicine

Rheumatology

11th Mar, 2026

The New England Journal of Medicine

Baker’s Cyst

Rheumatology

11th Mar, 2026

The Lancet

[Clinical Picture] Pneumatosis cystoides intestinalis in overlap syndrome

Rheumatology

11th Mar, 2026

The Lancet

[Viewpoint] Oral glucocorticoid pulse therapy: a modest change in clinical practice with major benefits

Rheumatology

11th Mar, 2026

The Lancet

[Review] The path to interception in psoriatic disease: from conceptual clarity to clinical translation

Rheumatology

11th Mar, 2026

The Lancet

[Articles] Clinical phenotypes, classification, and long-term outcomes of childhood-onset Sjögren's disease into adulthood: a single-centre cohort study

Rheumatology

11th Mar, 2026

The Lancet

[Articles] Cardiovascular risk factor control in antiphospholipid syndrome, and differences between primary and systemic lupus erythematosus-related antiphospholipid syndrome (SURF-SLE and APS project): a cross-sectional study of 1003 individuals from 11 countries

Rheumatology

11th Mar, 2026

The Lancet

[Articles] Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial

Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus

Related Articles

Baker’s Cyst

[Clinical Picture] Pneumatosis cystoides intestinalis in overlap syndrome

[Viewpoint] Oral glucocorticoid pulse therapy: a modest change in clinical practice with major benefits

[Review] The path to interception in psoriatic disease: from conceptual clarity to clinical translation

[Articles] Clinical phenotypes, classification, and long-term outcomes of childhood-onset Sjögren's disease into adulthood: a single-centre cohort study

[Articles] Cardiovascular risk factor control in antiphospholipid syndrome, and differences between primary and systemic lupus erythematosus-related antiphospholipid syndrome (SURF-SLE and APS project): a cross-sectional study of 1003 individuals from 11 countries

[Articles] Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial

Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus

Related Articles

Baker’s Cyst

[Clinical Picture] Pneumatosis cystoides intestinalis in overlap syndrome

[Viewpoint] Oral glucocorticoid pulse therapy: a modest change in clinical practice with major benefits

[Review] The path to interception in psoriatic disease: from conceptual clarity to clinical translation

[Articles] Clinical phenotypes, classification, and long-term outcomes of childhood-onset Sjögren's disease into adulthood: a single-centre cohort study

[Articles] Cardiovascular risk factor control in antiphospholipid syndrome, and differences between primary and systemic lupus erythematosus-related antiphospholipid syndrome (SURF-SLE and APS project): a cross-sectional study of 1003 individuals from 11 countries

[Articles] Long-term outcomes of abatacept in individuals at risk of developing rheumatoid arthritis (ALTO): a randomised, double-blind, placebo-controlled trial